Sugi Predict

Sugi Predict / Compounds / SCHEMBL487712

SCHEMBL487712

SCHEMBL487712

Cc1cc(CC(C)C)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UHRF1 Q96T88 1/20 0.46
▸ KCNQ2 O43526 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRB2 P47870 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ GRM5 P41594 1/20 0.37
▸ USP2 O75604 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ AAK1 Q2M2I8 1/20 0.35
▸ NOS3 P29474 1/20 0.35
▸ NOS1 P29475 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ NR3C2 P08235 1/20 0.35
▸ ADAMTS4 O75173 1/20 0.34
▸ MMP13 P45452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethoxycarbonyl Group SCHEMBL28010151 0.83 KCNQ2 (0.35) UHRF1KCNQ2GABRA1GABRB2KDM4E
SCHEMBL6560519 0.81 GABRA1 (0.42) GABRA1GABRB2KDM4EPOLBSMN1; SMN2
SCHEMBL14021971 0.80 UHRF1 (0.43) UHRF1KCNQ2GRM5AAK1NOS3
SCHEMBL4355540 0.78 UHRF1 (0.54) UHRF1KCNQ2GRM5NOS3NOS1
SCHEMBL17000195 0.78 POLB (0.44) GABRA1GABRB2KDM4EPOLBSMN1; SMN2
SCHEMBL17000172 0.78 GABRA1 (0.40) GABRA1GABRB2KDM4EPOLBSMN1; SMN2
SCHEMBL10159790 0.78 RECQL (0.57) GABRA1GABRB2KDM4EPOLBSMN1; SMN2
SCHEMBL18458630 0.78 GABRA1 (0.48) GABRA1GABRB2KDM4EPOLBSMN1; SMN2
SCHEMBL12880418 0.78 LOXL2 (0.57) KCNQ2GABRA1GABRB2KDM4EPOLB
SCHEMBL13349079 0.78 GABRA1 (0.40) GABRA1GABRB2KDM4EPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328126-B2 Norbornenylhydrocarbylene dihydrocarbylboranes and methods of making the same PROMERUS, LLC (US) 2016-05-03 — — US claimed
US-20150353582-A1 NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME PROMERUS, LLC (US) 2015-12-10 — — US claimed
WO-2014121008-A1 NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME PROMERUS, LLC (US) 2014-08-07 — — WO claimed
US-8106200-B2 Pyridine borane complexes BASF SE (DE) 2012-01-31 — — US claimed
US-20110207934-A1 PYRIDINE BORANE COMPLEXES BASF SE (DE) 2011-08-25 — — US claimed
EP-2066631-B1 PYRIDINE BORANE COMPLEXES BASF SE (DE) 2011-04-06 — — EP claimed
CN-101516846-A Pyridine borane complexes BASF AG (DE) 2009-08-26 — — CN claimed
US-11833144-B2 Treating autoimmune disease MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2023-12-05 — — US disclosed
EP-3784669-B1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMA (US) 2023-10-25 — — EP disclosed
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-10-05 — — US disclosed
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-10-05 — — US disclosed
US-20230310419-A1 COMPOUNDS AND METHODS FOR TREATING CANCER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2023-10-05 — — US disclosed
US-20230303562-A1 PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-09-28 — — US disclosed
EP-2091956-A1 DIALKYLBORANE AMINE COMPLEXES BASF SE (DE) 2009-08-26 — — EP disclosed
CN-101516846-A Pyridine borane complexes BASF AG (DE) 2009-08-26 — — CN disclosed
EP-2066631-A1 PYRIDINE BORANE COMPLEXES BASF SE (DE) 2009-06-10 — — EP disclosed
WO-2008055859-A1 DIALKYLBORANE AMINE COMPLEXES BASF SE (DE) 2008-05-15 — — WO disclosed
WO-2008034886-A1 PYRIDINE BORANE COMPLEXES BASF SE (DE) 2008-03-27 — — WO disclosed
US-7312201-B2 Tetracyclic bicyclolides ENANTA PHARMACEUTICALS, INC. (US) 2007-12-25 — — US disclosed
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION 2007-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303562-A1 PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP51A1, CYP4F11, WEE1 UHRF1 2345/4885KCNQ2 2673/4885GABRA1 1882/4885
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists HRH4, HRH3, HRH2 UHRF1 2606/4885KCNQ2 2545/4885GABRA1 1134/4885
US-20150353582-A1 NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME CYP8B1, BDKRB1, CYP1B1 UHRF1 1630/4885KCNQ2 3079/4885GABRA1 831/4885
US-11833144-B2 Treating autoimmune disease NR5A1, SSB, RBP4 UHRF1 3480/4885KCNQ2 3564/4885GABRA1 2490/4885
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF DPYD, PKD1, TYMP UHRF1 3674/4885KCNQ2 4109/4885GABRA1 3502/4885
US-20230310419-A1 COMPOUNDS AND METHODS FOR TREATING CANCER SCD, SCD5, CPT1B UHRF1 2372/4885KCNQ2 4614/4885GABRA1 3693/4885
US-20110207934-A1 PYRIDINE BORANE COMPLEXES NBAS, BRD8, PAXBP1 UHRF1 4406/4885KCNQ2 1588/4885GABRA1 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.